AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8409337 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously 3 times weekly after hemodialysis for 6 months
Number of subjects: 13
Study 8409337 — intervention group
Group type: EXPERIMENTAL
Intervention: Roferon A 3 MU
Number of subjects: 13
Study 3895947 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 60
Study 3895947 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/tobramycin
Number of subjects: 60
Study 30102825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 μg/kg/minute for a median duration of 6.0 hours)
Number of subjects: 264
Study 27090535 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R (restricted view of the larynx)
Number of subjects: 163
Study 27090535 — intervention group
Group type: COMPARATOR
Intervention: Group F (full view of the larynx)
Number of subjects: 163
Study 27090535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 163
Study 24384643 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day) + ASA (325 mg/day)
Number of subjects: 838
Study 24384643 — intervention group
Group type: COMPARATOR
Intervention: ASA (325 mg/day)
Number of subjects: 838
Study 22664411 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable food of high caloric density
Number of subjects: 0
Study 22664411 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable food of moderate caloric density
Number of subjects: 0
Study 22664411 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable food of low caloric density
Number of subjects: 0
Study 22664411 — intervention group
Group type: COMPARATOR
Intervention: High-calorie food
Number of subjects: 0
Study 22664411 — intervention group
Group type: COMPARATOR
Intervention: Moderate-calorie food
Number of subjects: 0
Study 22664411 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie food
Number of subjects: 0
Study 20650793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 30
Study 20650793 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane plus rocuronium anesthesia
Number of subjects: 30
Study 20650793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 19230215 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT + RP
Number of subjects: 20
Study 19230215 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 20
Study 16279582 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer involvement in the PRISM trial
Number of subjects: 0
Study 12022539 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution for cardiac preservation
Number of subjects: 70
Study 7557846 — intervention group
Group type: EXPERIMENTAL
Intervention: daily IFN‐alpha
Number of subjects: 35
Study 7557846 — intervention group
Group type: EXPERIMENTAL
Intervention: alternate‐day IFN‐alpha
Number of subjects: 35
Study 7557846 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 35
Study 7557846 — intervention group
Group type: EXPERIMENTAL
Intervention: responders (treated patients)
Number of subjects: 35
Study 7557846 — intervention group
Group type: EXPERIMENTAL
Intervention: nonresponders (treated patients)
Number of subjects: 35
Study 7557846 — intervention group
Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 35
Study 2190251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate infusion
Number of subjects: 20
Study 2190251 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 773499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 90
Study 773499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 90
Study 773499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 90
Study 773499 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 90
Study 773499 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 31683483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic Acids (CGA) beverage (553.6 mg/bottle) twice daily for 12 weeks
Number of subjects: 34
Study 31683483 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 34
Study 28961602 — intervention group
Group type: EXPERIMENTAL
Intervention: Video review of performance at day 3
Number of subjects: 32
Study 28961602 — intervention group
Group type: COMPARATOR
Intervention: No video review of performance at day 3
Number of subjects: 32
Study 25542620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care (colonoscopy at 6 months)
Number of subjects: 174
Study 25542620 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no colonoscopy)
Number of subjects: 174
Study 25542620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care (step-up treatment for recurrence)
Number of subjects: 174
Study 25542620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care (no change in therapy)
Number of subjects: 174
Study 25542620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care and Standard care
Number of subjects: 174
Study 24800381 — intervention group
Group type: EXPERIMENTAL
Intervention: LGIE (Low Glycaemic Index Education)
Number of subjects: 60
Study 24800381 — intervention group
Group type: COMPARATOR
Intervention: CHDR (Conventional Healthy Dietary Recommendations)
Number of subjects: 60
Study 21725881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium aescinate (5 mg)
Number of subjects: 75
Study 21725881 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sodium aescinate (10 mg)
Number of subjects: 75
Study 21725881 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 75
Study 19995138 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations (160/9 microg) twice daily
Number of subjects: 257
Study 19995138 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide pMDI 80 microg x 2 inhalations (160 microg) twice daily
Number of subjects: 257
Study 19995138 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly recall
Number of subjects: 257
Study 19995138 — intervention group
Group type: COMPARATOR
Intervention: daily recall
Number of subjects: 257
Study 16790652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA)
Number of subjects: 50
Study 16790652 — intervention group
Group type: COMPARATOR
Intervention: 6% Hydroxyethyl Starch (HES)
Number of subjects: 50
Study 14990784 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (10 mg/day for 48 weeks)
Number of subjects: 0
Study 11006177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged coasting (withholding gonadotrophins while continuing pituitary down-regulation)
Number of subjects: 15
Study 11006177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged coasting
Number of subjects: 15
Study 9314858 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective aneurysm repair
Number of subjects: 46
Study 8317315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (systemic pretreatment)
Number of subjects: 0
Study 8317315 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (topical pretreatment)
Number of subjects: 0
Study 8317315 — intervention group
Group type: COMPARATOR
Intervention: Saline or vehicle (control)
Number of subjects: 0
Study 3027836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg once daily for five consecutive days)
Number of subjects: 40
Study 3027836 — intervention group
Group type: COMPARATOR
Intervention: 2.5% selenium sulfide shampoo (once daily application for seven days)
Number of subjects: 40
Study 29432262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 3-D image navigation
Number of subjects: 49
Study 29432262 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 49
Study 27738639 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 28
Study 25044383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline 400 mg/thrice-weekly
Number of subjects: 71
Study 25044383 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 22232050 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg per day)
Number of subjects: 74
Study 22232050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 21081728 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus sorafenib (60 mg/m² doxorubicin every 21 days + 400 mg sorafenib twice daily)
Number of subjects: 96
Study 21081728 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (60 mg/m² doxorubicin every 21 days + placebo)
Number of subjects: 96
Study 21081728 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus sorafenib
Number of subjects: 96
Study 21081728 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 96
Study 18425403 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) measured by accelerometers and lower extremity strength by a jump-and-reach test in boys (n = 128)
Number of subjects: 269
Study 18425403 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA) measured by accelerometers and lower extremity strength by a jump-and-reach test in girls (n = 141)
Number of subjects: 269
Study 15804468 — intervention group
Group type: COMPARATOR
Intervention: Tower Trainer
Number of subjects: 46
Study 15804468 — intervention group
Group type: COMPARATOR
Intervention: LapSim
Number of subjects: 46
Study 12909072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate control
Number of subjects: 252
Study 12909072 — intervention group
Group type: COMPARATOR
Intervention: Cardioversion and maintenance of sinus rhythm
Number of subjects: 252
Study 12909072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 252
Study 12909072 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 252
Study 12909072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 252
Study 10471824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 0
Study 10471824 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis neutrophils
Number of subjects: 0
Study 10471824 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis monocytes
Number of subjects: 0
Study 8966144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin level in bronchoalveolar lavage fluid (BAL) in patients with extrinsic allergic alveolitis
Number of subjects: 12
Study 8966144 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 12
Study 1920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education courses
Number of subjects: 662
Study 1920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials and videotapes by mail
Number of subjects: 662
Study 1920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials by mail
Number of subjects: 662
Study 1920269 — intervention group
Group type: COMPARATOR
Intervention: No Education Group (Control)
Number of subjects: 662
Study 6314661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (surgical and drug therapy including CCNU)
Number of subjects: 0
Study 6314661 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomycetin as part of combined therapy
Number of subjects: 0
Study 6314661 — intervention group
Group type: COMPARATOR
Intervention: Control group (cancer patients not receiving combined therapy)
Number of subjects: 0
Study 30797722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device application (app) for drug preparation
Number of subjects: 128
Study 30797722 — intervention group
Group type: COMPARATOR
Intervention: Infusion‐rates table
Number of subjects: 128
Study 30797722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device application (app)
Number of subjects: 128
Study 27869312 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted pelvic muscle therapy (BAPFMT) with the MAPLe
Number of subjects: 58
Study 27869312 — intervention group
Group type: COMPARATOR
Intervention: Control group (toilet behavior and lifestyle instructions)
Number of subjects: 58
Study 25476993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose total skin electron beam therapy (12 Gy, 1 Gy per fraction over 3 weeks)
Number of subjects: 33
Study 23769122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg
Number of subjects: 0
Study 23769122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0
Study 23769122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21707601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intervention
Number of subjects: 75
Study 21707601 — intervention group
Group type: EXPERIMENTAL
Intervention: T/K intervention
Number of subjects: 75
Study 21707601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (oral+T/K)
Number of subjects: 75
Study 21707601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 19538914 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based intervention (PBI)
Number of subjects: 724
Study 19538914 — intervention group
Group type: COMPARATOR
Intervention: Intervention as usual (alcohol fact sheet for parents)
Number of subjects: 724
Study 16434253 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation
Number of subjects: 40
Study 16434253 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 40
Study 14716800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 GG genotype (n = 263)
Number of subjects: 424
Study 14716800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 GA genotype (n = 147)
Number of subjects: 424
Study 14716800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism + 148 AA genotype (n = 20)
Number of subjects: 424
Study 14716800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C gene polymorphism -82 C allele homozygotes
Number of subjects: 424
Study 14716800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking history
Number of subjects: 424
Study 11606448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily for 12 months)
Number of subjects: 85
Study 11606448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically appearing tablets daily for 12 months)
Number of subjects: 85
Study 9219507 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT at 12 mg/kg daily for 1 year
Number of subjects: 224
Study 8489058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 ng/ml
Number of subjects: 77
Study 8489058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 10 ng/ml
Number of subjects: 77
Study 8489058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 1.67 ng/ml
Number of subjects: 77
Study 8489058 — intervention group
Group type: COMPARATOR
Intervention: No fentanyl (control group)
Number of subjects: 77
Study 2893561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5.0 micrograms
Number of subjects: 240
Study 29317362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Block prior to Pulsed Radiofrequency (DRG-PRF)
Number of subjects: 60
Study 29317362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of DRG-PRF
Number of subjects: 60
Study 28418750 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian/Pacific Islander women
Number of subjects: 318
Study 28418750 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian American women
Number of subjects: 318
Study 26226938 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS (2 mA)
Number of subjects: 24
Study 26226938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham HD-tDCS)
Number of subjects: 24
Study 23625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 25
Study 23625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg once daily)
Number of subjects: 25
Study 23625113 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study 21436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls-related self-efficacy assessed using the Activities-specific Balance Confidence Scale
Number of subjects: 135
Study 21436152 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence Scale
Number of subjects: 135
Study 18958561 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 42
Study 18958561 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (5-fluorouracil 200 mg/m2/day and 5040 Gy radiotherapy)
Number of subjects: 42
Study 16874148 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend warrior (n=13, two sessions per week on consecutive days, 75 min each, intensity 90% of the anaerobic threshold)
Number of subjects: 38
Study 16874148 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training (n=12, five sessions per week, 30 min each, same intensity as weekend warrior)
Number of subjects: 38
Study 16874148 — intervention group
Group type: COMPARATOR
Intervention: Control (n=13, no training)
Number of subjects: 38
Study 12819941 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered as a constant 72-h i.v. infusion every 2 weeks at a dose of 47 microg/m2 per hour
Number of subjects: 20
Study 12819941 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at 59 microg/m2 per hour
Number of subjects: 20
Study 12819941 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at lower doses
Number of subjects: 20
Study 12819941 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at 47 microg/m2 per hour
Number of subjects: 20
Study 12819941 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-aminocamptothecin (9-AC) administered at various dose levels
Number of subjects: 20
Study 11055449 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital (DH)
Number of subjects: 668
Study 11055449 — intervention group
Group type: COMPARATOR
Intervention: Traditional Outpatient Programs (OP)
Number of subjects: 668
Study 9387348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group A)
Number of subjects: 62
Study 9387348 — intervention group
Group type: COMPARATOR
Intervention: Physical treatment (Group B)
Number of subjects: 62
Study 1432282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg/dose, given in three doses 8 hours apart, final dose 1 hour before extubation
Number of subjects: 51
Study 1432282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, equal volume to dexamethasone)
Number of subjects: 51
Study 2857212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy) for 90 days followed by azathioprine and prednisolone (Aza and P)
Number of subjects: 86
Study 2857212 — intervention group
Group type: COMPARATOR
Intervention: Control group (Aza and P from day 0)
Number of subjects: 86
Study 30563758 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus manipulation (n=31)
Number of subjects: 61
Study 30563758 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=30)
Number of subjects: 61
Study 30286342 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme (24-week duration)
Number of subjects: 0
Study 27441475 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care (PCC) plus usual care
Number of subjects: 199
Study 27441475 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 199
Study 25171133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loading of sodium valproate (20 mg/kg oral single-dose on the first day, then 10-15 mg/kg daily)
Number of subjects: 90
Study 25171133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous loading of sodium valproate (20 mg/kg intravenous injection on the first day, then 10-15 mg/kg orally)
Number of subjects: 90
Study 25171133 — intervention group
Group type: COMPARATOR
Intervention: Oral maintenance administration of sodium valproate (15-20 mg/kg daily from the beginning)
Number of subjects: 90
Study 22351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bolus dose atropine (group A)
Number of subjects: 156
Study 22351300 — intervention group
Group type: COMPARATOR
Intervention: Rapidly incremental doses of atropine followed by infusion (group B)
Number of subjects: 156
Study 20153039 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 1006
Study 20153039 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil
Number of subjects: 1006
Study 17512638 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 7
Study 17512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 7
Study 17512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 7
Study 17512638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 7
Study 16371681 — intervention group
Group type: EXPERIMENTAL
Intervention: Group workshops and single one-on-one tutorials with parents, teachers, and providers about the evaluation and treatment of ADHD.
Number of subjects: 243
Study 16371681 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 243
Study 12143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42
Study 12143910 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 42
Study 10453230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav (amoxycilline and clavulanic acid)
Number of subjects: 150
Study 10453230 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ampicilline (control)
Number of subjects: 150
Study 7628886 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit of seven exercises performed for 30 seconds each, repeated five times.
Number of subjects: 20